AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12488406 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg every 28 days for 2 years)
Number of subjects: 1640
Study 12488406 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy (six 28-day cycles)
Number of subjects: 1640
Study 9797818 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron via drip infusion with 100 ml of normal saline 30 minutes prior to CDDP administration (Group A)
Number of subjects: 34
Study 9797818 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct injection of granisetron into the CDDP containing bottle (Group B)
Number of subjects: 34
Study 9797818 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (both methods)
Number of subjects: 34
Study 7661057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple identical angiographic projections
Number of subjects: 348
Study 2473539 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 6
Study 2473539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Iloprost
Number of subjects: 6
Study 2473539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Placebo
Number of subjects: 6
Study 2473539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2473539 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6
Study 2473539 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 6
Study 338009 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate inhalation (800 microgram daily)
Number of subjects: 18
Study 338009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31482848 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelactation services (unlimited, on-demand video calls with lactation consultants through a mobile phone app)
Number of subjects: 102
Study 31482848 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelactation services
Number of subjects: 102
Study 31482848 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelactation users
Number of subjects: 102
Study 28249970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (local bisphosphonate treatment)
Number of subjects: 60
Study 28249970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline treatment)
Number of subjects: 60
Study 26188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin pharmacogenetics algorithms (10 selected algorithms)
Number of subjects: 193
Study 26188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Wadelius et al. algorithm
Number of subjects: 193
Study 26188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gage et al. algorithm
Number of subjects: 193
Study 26188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms in general
Number of subjects: 193
Study 26188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Wadelius et al. and Miao et al. algorithms
Number of subjects: 193
Study 23952889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of NAC
Number of subjects: 111
Study 23952889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,400 mg of NAC
Number of subjects: 111
Study 23952889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 21412846 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (300 mg/day)
Number of subjects: 51
Study 21412846 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15 mg/day)
Number of subjects: 51
Study 21412846 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (6 mg/day)
Number of subjects: 51
Study 19365587 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 450 mg loading and 75 mg/d thereafter added to standard reperfusion therapy (group 2, n: 85)
Number of subjects: 175
Study 19365587 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological reperfusion therapy (group 1, n: 90)
Number of subjects: 175
Study 17460488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus LB (Lacteol) plus oral rehydration salts (ORS)
Number of subjects: 80
Study 17460488 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral rehydration salts (ORS)
Number of subjects: 80
Study 17460488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus LB (Lacteol)
Number of subjects: 80
Study 17460488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15492476 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric dosing of nitrates (n=153)
Number of subjects: 573
Study 15492476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of nitrates (n=86)
Number of subjects: 573
Study 15492476 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (n=334)
Number of subjects: 573
Study 12146181 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9133767 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine and therapy
Number of subjects: 33
Study 9133767 — intervention group
Group type: COMPARATOR
Intervention: Placebo and therapy
Number of subjects: 33
Study 8432296 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (10 mg bolus injection + 5000 IU heparin bolus injection, followed by 90 mg alteplase over 3 h)
Number of subjects: 270
Study 8432296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 mg iv over 5 min)
Number of subjects: 270
Study 8432296 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 million U over 1 h)
Number of subjects: 270
Study 3123043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 10
Study 29524796 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 70
Study 29524796 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual surgery
Number of subjects: 70
Study 26488178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 2898
Study 26488178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2898
Study 24956323 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention led by a community health worker
Number of subjects: 0
Study 24956323 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention plus patient and family communication activation intervention
Number of subjects: 0
Study 24956323 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention plus problem-solving intervention
Number of subjects: 0
Study 21874575 — intervention group
Group type: COMPARATOR
Intervention: Chevron osteotomy (CO)
Number of subjects: 72
Study 21874575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron‐Akin double osteotomy (CAO)
Number of subjects: 72
Study 20156955 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary endpoint (TLOVR in 13 trials)
Number of subjects: 51
Study 20156955 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological efficacy endpoint
Number of subjects: 51
Study 17868006 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide (50-100 mg/day)
Number of subjects: 0
Study 17868006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16197773 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfectant wipe
Number of subjects: 36
Study 16197773 — intervention group
Group type: COMPARATOR
Intervention: Dry wipe (Control)
Number of subjects: 36
Study 12135034 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 g polyethylene glycol (PEG) laxative
Number of subjects: 24
Study 12135034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12135034 — intervention group
Group type: EXPERIMENTAL
Intervention: 51 g polyethylene glycol (PEG) laxative
Number of subjects: 24
Study 12135034 — intervention group
Group type: EXPERIMENTAL
Intervention: 85 g polyethylene glycol (PEG) laxative
Number of subjects: 24
Study 10426889 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine
Number of subjects: 0
Study 10426889 — intervention group
Group type: COMPARATOR
Intervention: Proprietary base cream
Number of subjects: 0
Study 10426889 — intervention group
Group type: COMPARATOR
Intervention: No application (negative control)
Number of subjects: 0
Study 7546114 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thermal pulsed high-frequency electromagnetic energy treatment for 30 minutes twice daily for 12 weeks
Number of subjects: 30
Study 7546114 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 7546114 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thermal pulsed high-frequency electromagnetic energy treatment
Number of subjects: 30
Study 1400055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance training (30 isometric extension maximal voluntary contractions per day, 3 times per week for 8 weeks)
Number of subjects: 20
Study 1400055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 4042525 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 60
Study 4042525 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 60
Study 4042525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 60
Study 4042525 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg and 100 mg combined)
Number of subjects: 60
Study 29275880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d)
Number of subjects: 2153
Study 29275880 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Rosuvastatin
Number of subjects: 2153
Study 29275880 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan with hydrochlorothiazide (HCTZ; 16 mg/12.5 mg/d)
Number of subjects: 2153
Study 29275880 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Candesartan with HCTZ
Number of subjects: 2153
Study 29275880 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Rosuvastatin + Cand+HCTZ)
Number of subjects: 2153
Study 29275880 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 2153
Study 27050628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training (Cogmed; n=13)
Number of subjects: 27
Study 27050628 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive training (active placebo; n=14)
Number of subjects: 27
Study 26683478 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPIFED (Healthy APproach to weIght management and Food in Eating Disorders)
Number of subjects: 100
Study 26683478 — intervention group
Group type: COMPARATOR
Intervention: CBT-E (Cognitive Behavioural Therapy-Enhanced)
Number of subjects: 100
Study 26683478 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPIFED
Number of subjects: 100
Study 26683478 — intervention group
Group type: COMPARATOR
Intervention: CBT-E
Number of subjects: 100
Study 23742208 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored self-management intervention
Number of subjects: 0
Study 23742208 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 21392751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic anteroposterior x‐ray
Number of subjects: 45
Study 19049375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 211
Study 19049375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 16990190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin (2.5, 5, 7.5, or 10 g intravenous doses)
Number of subjects: 136
Study 16990190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 12959627 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate
Number of subjects: 0
Study 11020518 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH alone
Number of subjects: 22
Study 11020518 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist combined with FSH
Number of subjects: 22
Study 2191020 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic alcoholization of lesions preceded by intragastric instillation of norepinephrine
Number of subjects: 28
Study 2191020 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 28
Study 6985989 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0
Study 6985989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide treatment
Number of subjects: 0
Study 6985989 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31564269 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises (DBE) given twice daily with 5-10 repetitions for 15-30 minutes for 14 sessions
Number of subjects: 30
Study 31564269 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry (ISM) with steam inhalation and nebulization with beta 2 agonist for 15-20 minutes for 35-45 minutes twice daily for 7 days
Number of subjects: 30
Study 27862831 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 80
Study 27862831 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80
Study 26264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring-eccentric (ECC) exercise protocol
Number of subjects: 32
Study 26264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable-squatting (UNS) exercise protocol
Number of subjects: 32
Study 26264751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 24389433 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m² and carboplatin (AUC 6 mg/min/ml) plus panitumumab (2.5 mg/kg)
Number of subjects: 19
Study 24389433 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m² and carboplatin (AUC 6 mg/min/ml) without panitumumab
Number of subjects: 19
Study 20579989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone, 400 mg twice a day from the day of embryo transfer
Number of subjects: 435
Study 20579989 — intervention group
Group type: COMPARATOR
Intervention: No progesterone support
Number of subjects: 435
Study 19702079 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI 1 mL/kg after intubation and before blocking the aorta (Group E1)
Number of subjects: 32
Study 19702079 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI 1 mL/kg after opening the aorta (Group E2)
Number of subjects: 32
Study 19702079 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI 0.5 mL/kg twice, before blocking and after opening the aorta (Group E3)
Number of subjects: 32
Study 19702079 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1 mL/kg after intubation (Group C)
Number of subjects: 32
Study 16551919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine 15 mL on each side
Number of subjects: 45
Study 16551919 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic wound infiltration with 0.25% bupivacaine 20 mL
Number of subjects: 45
Study 16551919 — intervention group
Group type: COMPARATOR
Intervention: No regional block administered (Control)
Number of subjects: 45
Study 12571670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based intervention (tasting sweet red pepper for 8 daily sessions)
Number of subjects: 49
Study 12571670 — intervention group
Group type: COMPARATOR
Intervention: Reward-based intervention (choosing a sticker after eating red pepper)
Number of subjects: 49
Study 12571670 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 49
Study 10933099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscopy
Number of subjects: 51
Study 9331228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg oral alprazolam
Number of subjects: 84
Study 9331228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg oral alprazolam
Number of subjects: 84
Study 9331228 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg oral alprazolam
Number of subjects: 84
Study 9331228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 13 with undesirable members (11:2 proportion)
Number of subjects: 145
Study 8355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 52 with desirable members (2:11 proportion)
Number of subjects: 145
Study 8355426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 39
Number of subjects: 145
Study 2441631 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural anesthesia with 12 ml of 2% lidocaine at T12 interspace
Number of subjects: 80
Study 2441631 — intervention group
Group type: COMPARATOR
Intervention: Single dose epidural anesthesia with 2% lidocaine-0.2% tetracaine
Number of subjects: 80
Study 2441631 — intervention group
Group type: COMPARATOR
Intervention: Single dose epidural anesthesia with 2% lidocaine-fentanyl 50 micrograms
Number of subjects: 80
Study 2441631 — intervention group
Group type: COMPARATOR
Intervention: Single dose epidural anesthesia with bupivacaine 0.5%
Number of subjects: 80
Study 30135045 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention (Living positive with HIV)
Number of subjects: 188
Study 30135045 — intervention group
Group type: COMPARATOR
Intervention: Attention-only waiting-list control
Number of subjects: 188
Study 26705672 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Pressure Release (MPR)
Number of subjects: 31
Study 26705672 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR/MKT (Manual Pressure Release combined with Kinesio taping)
Number of subjects: 31
Study 25637294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) in addition to optimal medical therapy (OMT)
Number of subjects: 600
Study 25637294 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 600
Study 25637294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 600
Study 23076819 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin 2.25 % + abamectin 1.25 %
Number of subjects: 100
Study 23076819 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin 3.15 %
Number of subjects: 100
Study 23076819 — intervention group
Group type: EXPERIMENTAL
Intervention: doramectin 3.15 %
Number of subjects: 100
Study 23076819 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 100
Study 19837485 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE)
Number of subjects: 12
Study 19837485 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 12
Study 19082229 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone 0.5 mg/kg in 2 divided doses plus topical clobetasol ointment for 2 weeks
Number of subjects: 40
Study 19082229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxyfylline tablet 1200 mg/day in 3 divided doses for 2 weeks
Number of subjects: 40
Study 16542472 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated protein C (rhAPC)
Number of subjects: 0
Study 12793211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleach plus light (using LumaArch, Optilux 500, and Zoom!)
Number of subjects: 15
Study 12793211 — intervention group
Group type: COMPARATOR
Intervention: Bleach alone (control group)
Number of subjects: 15
Study 10915324 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only intervention
Number of subjects: 383
Study 10915324 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/environment intervention
Number of subjects: 383
Study 10915324 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 383
Study 10915324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 383
Study 8857071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (L)
Number of subjects: 16
Study 8857071 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (A)
Number of subjects: 16
Study 1387609 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 4 ng.kg-1.min-1
Number of subjects: 14
Study 1387609 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 8 ng.kg-1.min-1
Number of subjects: 14
Study 1387609 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 16 ng.kg-1.min-1
Number of subjects: 14
Study 1387609 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (V)
Number of subjects: 14
Study 1387609 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF (4, 8, 16 ng.kg-1.min-1)
Number of subjects: 14
Study 6537871 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast rich in vitamin A (337 micrograms of retinol equivalents, 48% as retinol and 52% as carotenoids)
Number of subjects: 60
Study 6537871 — intervention group
Group type: COMPARATOR
Intervention: Fasting blood samples
Number of subjects: 60
Study 31664347 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted hip-hop dance practice (SG)
Number of subjects: 18
Study 31664347 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 0.5 mg/day
Number of subjects: 0
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg/day
Number of subjects: 0
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 2 mg/day
Number of subjects: 0
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan 4 mg/day
Number of subjects: 0
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan ≥1 mg/day
Number of subjects: 0
Study 28940451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 0
Study 27764880 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based strategy including thoracic, abdominal, and pelvic CT in combination with fecal occult blood test
Number of subjects: 195
Study 27764880 — intervention group
Group type: COMPARATOR
Intervention: Personalized strategy based on physicians' clinical judgment and patients' preferences
Number of subjects: 195
Study 24848782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (SNB) in addition to femoral nerve block (FNB)
Number of subjects: 46